Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 572 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: NASH (Non-Alcoholic Steatohepatitis) Clear all
Completed Not applicable Interventional

Treating Pediatric NAFLD with Nutrition

NCT05499585
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Liver Diseases, Liver Fat, Hepatic Steatosis, Nutritional and Metabolic Disease
Interventions
Whole Dairy
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
10 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 14, 2026, 10:13 AM EDT
Recruiting Phase 2 Interventional

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07288138
View directory record Official record
Conditions
Metabolic Dysfunction-associated Steatohepatitis
Interventions
Placebo, ECC4703, ECC0509
Drug
Lead sponsor
Eccogene
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
68
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 14, 2026, 10:13 AM EDT
Withdrawn Phase 4 Interventional

Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI

NCT02263677
View directory record Official record
Conditions
Type 2 Diabetes, Non-alcoholic Fatty Liver Disease
Interventions
Sitagliptin
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 14, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis

NCT02421094
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
GR-MD-02, Placebo
Drug
Lead sponsor
Galectin Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 14, 2026, 10:13 AM EDT
Completed Phase 2 Interventional

Leptin to Treat Lipodystrophy

NCT00005905
View directory record Official record
Conditions
Lipodystrophy
Interventions
hu Leptin (A-100)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 14, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)

NCT04198805
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Fatty Liver, Non-Alcoholic Steatohepatitis
Interventions
Vitamin E [(all-rac)-α-tocopheryl acetate], Omega-3 fatty acid (DHA EE), Omega-3 fatty acid (DHA EE) & Vitamin E [(all-rac)-α-tocopheryl acetate], Placebo
Dietary Supplement · Combination Product · Other
Lead sponsor
Naga P. Chalasani
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Chandler, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 14, 2026, 10:13 AM EDT
Completed Not applicable Interventional

Effects of Dietary Fructose Reduction in Children With Hepatic Steatosis

NCT01188083
View directory record Official record
Conditions
Non-alcoholic Fatty-liver Disease
Interventions
Fructose Drink, Glucose Drink
Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
11 Years to 18 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2013 · Synced Oct 14, 2026, 10:13 AM EDT
Terminated Phase 2 Interventional Results available

Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency

NCT02193867
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency
Interventions
Sebelipase Alfa
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 8 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 14, 2026, 10:13 AM EDT
Completed Phase 3 Interventional

S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis

NCT00108589
View directory record Official record
Conditions
Hepatitis
Interventions
S-adenosylmethionine
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 14, 2026, 10:13 AM EDT
Completed Phase 1 Interventional

Phase I Trial of Silymarin for Chronic Liver Diseases

NCT00389376
View directory record Official record
Conditions
Hepatitis C, Non-Alcoholic Fatty Liver Disease
Interventions
Placebo, Silymarin
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2008 · Synced Oct 14, 2026, 10:13 AM EDT
Completed No phase listed Observational

A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

NCT05320146
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
MRI-PDFF
Other
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Timeline
2022 – 2023
U.S. locations
9
States / cities
Chandler, Arizona • Tucson, Arizona • Panorama City, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 14, 2026, 10:13 AM EDT
Recruiting Phase 2 Interventional

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

NCT05519475
View directory record Official record
Conditions
Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
Interventions
ALN-HSD, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
61
States / cities
Flagstaff, Arizona • Peoria, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 14, 2026, 10:13 AM EDT
Completed Not applicable Interventional

Feasibility of Immersive Virtual Reality Dietician Program in Metabolic-dysfunction Associated Steatotic Liver Disease

NCT06215131
View directory record Official record
Conditions
Fatty Liver, Nonalcoholic, Weight Loss, Virtual Reality, Implementation Science
Interventions
In-person dietary weight loss counseling, Virtual reality dietary weight loss counseling
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 14, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)

NCT04929483
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
BIO89-100, Placebo
Drug
Lead sponsor
89bio, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
88
States / cities
Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 14, 2026, 10:13 AM EDT
Completed No phase listed Observational

Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease

NCT05669677
View directory record Official record
Conditions
Chronic or Recovered Hepatitis B, Chronic or Recovered Hepatitis C, Chronic or Recovered Hepatitis D, NAFLD, NASH
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 14, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)

NCT06482112
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Liver Disease
Interventions
Efinopegdutide
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
36
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 14, 2026, 10:13 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study

NCT04550481
View directory record Official record
Conditions
Hepatocellular Carcinoma, Nonalcoholic Steatohepatitis
Interventions
Biospecimen Collection, Lisinopril, Liver Ultrasonographic Elastography, Magnetic Resonance Elastography, Magnetic Resonance Imaging, Proton Density Fat Fraction, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Rochester, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 14, 2026, 10:13 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)

NCT04807868
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Standard of care liver biopsy, Fibroscan, Biospecimen Collection
Procedure · Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years and older
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 14, 2026, 10:13 AM EDT
Terminated No phase listed Observational

Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo

NCT03479125
View directory record Official record
Conditions
Liver Diseases, Liver Fibrosis, Liver Cirrhosis, NASH Fibrosis, Decompensated Non-Alcoholic Steatohepatitis Cirrhosis, Orthotopic Liver Transplantation
Interventions
Ultrasound
Diagnostic Test
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Rialto, California • Tulsa, Oklahoma • Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 14, 2026, 10:13 AM EDT
Not listed Not applicable Interventional

Study to Evaluate the Effect of RGMA001 on Patients With Non Alcoholic Fatty Liver Disease (NAFLD)

NCT01511523
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
RGMA001, Sugar Pill
Dietary Supplement
Lead sponsor
Biovil Research Group, LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Fayetteville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 14, 2026, 10:13 AM EDT
Terminated Phase 1 Interventional Results available

A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)

NCT06007651
View directory record Official record
Conditions
Dyslipidemias, Non-Alcoholic Fatty Liver Disease
Interventions
LY3885125, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 14, 2026, 10:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study in Healthy Adults Evaluating PF-07202954

NCT04857437
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Liver Fibrosis
Interventions
PF-07202954 Repeat Dose, PF-07202954 Single Dose, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Oct 14, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease

NCT01963845
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Oct 14, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy

NCT02654977
View directory record Official record
Conditions
Familial Partial Lipodystrophy, Nonalcoholic Steatohepatitis, NAFLD
Interventions
Metreleptin
Drug
Lead sponsor
University of Michigan
Other
Eligibility
5 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 14, 2026, 10:13 AM EDT